Merck · 7 hours ago
2026 Future Talent Program – Discovery Immunology – Co-op (Cambridge, MA)
Merck is a global healthcare leader specializing in prescription medicines, vaccines, and animal health products. They are seeking co-op candidates for their Discovery Immunology group in Cambridge, where students will engage in drug discovery efforts and collaborate with experienced colleagues while learning key techniques in immunology and molecular biology.
BiotechnologyHealth CareMedicalPharmaceutical
Responsibilities
Co-op students will be part of a highly collaborative and innovative scientific culture with the ultimate goal of learning new biology and chemistry and establishing new technologies that drive therapeutic development
Students will be exposed to immunology both within the Cambridge site and other company sites across the country
Co-op students will work within a diverse group studying the role of novel targets in the context of inflammatory and autoimmune indications
Qualification
Required
Must be currently enrolled in school (through the co-op term) as an undergraduate or graduate student majoring in biological sciences or a related field
Must be available for a 4–6-month period starting mid-2026
Must have availability to work full-time on site in Cambridge, MA
Preferred
Basic knowledge of cell biology, immunology, molecular biology, and/or related wet lab techniques
Prior experience with mammalian cell culture, flow cytometry and/or immunoassays
Highly motivated and driven and willing to take initiative to learn new science
Strong team player
Excellent oral and written communication skills
Comfortable using a PC computer and proficient in Windows-based operating systems and basic applications, such as spreadsheets and databases
3.2 GPA or higher
Company
Merck
Merck is a biopharmaceutical company that offers medicines and vaccines for various diseases.
Funding
Current Stage
Public CompanyTotal Funding
$5.59MKey Investors
Private Capital AdvisorsGavi, the Vaccine Alliance
2018-11-25Post Ipo Equity· $0.59M
2016-01-21Series Unknown· $5M
1980-12-19IPO
Leadership Team
Recent News
Company data provided by crunchbase